|
|
|||||||||||||||||||||||||||||||||||||||
  IDEAYA Biosciences Inc (IDYA) IDEAYA Biosciences is a synthetic lethality-focused precision medicine oncology company engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Co.'s primary synthetic lethality product candidate is IDE397, a clinical-stage methionine adenosyltransferase 2a inhibitor for patients with solid tumors having methylthioadenosine phosphorylase deletions. Co. is enrolling patients into a Phase 1 clinical trial designated as IDE397-001 to evaluate IDE397. Co. is targeting poly (ADP-ribose) glycohydrolase for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures.
|
|
|||||||||||||||||||||||||||||||||||||||
Free IDYA Email Alerts:
IDEAYA Biosciences Inc (IDYA) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.